UCB maintains momentum with Bimzelx in psoriasis

Belgian drugmaker UCB (Euronext: UCB) has announced the presentation of new four-year data in patients with moderate to severe plaque psoriasis treated with bimekizumab, the company’s IL-17A and IL-17F inhibitor that is marketed as Bimzelx.

These post-hoc analyses include maintenance of response through four years in Bimzelx patients who achieved near-complete or complete skin clearance after one year, and the clinical response up to four years in patients switching to the drug following an inadequate response to either adalimumab, ustekinumab, or secukinumab—treatments that were initially marketed under the brand names Humira, Stelara and Cosentyx.

The data are being presented at the 33rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands.